Press releases
Browse GSK global press releases issued since 2009. Search them by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
GlaxoSmithKline (GSK) shows sign of things to come at London 2012 Olympic and Paralympic Games
2012 provider, GSK, unveils sign celebrating its scientific contribution to the Games
-
GSK awarded contract by BARDA to support research on potential novel antibiotic
GSK & BARDA's contract to support the development of a potentially new antibiotic against hospital Gram negative and biothreat pathogens.
-
GSK takes minority stake in new spin out Autifony Therapeutics
GSK announced its wholly-owned subsidiary will receive 25.4% equity stake in Autifony Therapeutics Limited alongside other investors.
-
GSK and Impax announce positive topline results of ASCEND-PD Phase III study of IPX066 in Advanced Parkinson’s disease
IPX066 demonstrated statistically significant improvement over carbidopa-levodopa plus entacapone in reducing off time % during waking hours
-
GSK and Enigma Diagnostics announce collaboration on assay development and commercialisation of Enigma’s ML platform
GSK & Enigma announced agreements for the supply of Enigma ML system for respiratory tests for use on its real-time PCR technology platform.
-
Regulatory Update: GSK and XenoPort submit supplemental New Drug Application to FDA for Horizant™ in postherpetic neuralgia
GSK & XNPT announced sNDA submitted to FDA for approval of Horizant tablets for the management of PHN in adults.
-
Regulatory update – Stiefel, a GSK company, files NDA for tazarotene foam
Stiefel announced it's submitted a NDA to the FDA for tazarotene foam for the topical treatment of facial acne vulgaris in patients 12+.
-
GSK delivers strong Q2 performance with underlying sales growth* of 5%, increased pipeline visibility and dividend of 16p, up 7%
Full details of GSK's results for the second quarter of 2011 can be found in the
-
GlaxoSmithKline European regulatory update on Pandemrix™
GSK announced EMA's CHMP has recommended an update to the product label for the H1N1 influenza vaccine, Pandemrix.
-
GlaxoSmithKline and Human Genome Sciences receive European authorisation for Benlysta® (belimumab)
GSK & HSG announced, EC has granted marketing authorisation for Benlysta as therapy in patients with active autoantibody-positive SLE.
-
EU and US Regulatory Update - Votrient® (pazopanib)
GSK announced it's submitted a Marketing Authorisation Application to EMA for Votrient, the treatment of patients with advanced STR.
-
London 2012 partner, GlaxoSmithKline, shares scientific expertise with World Anti-Doping Agency to help fight against abuse of drugs in sport
GSK signed a long-term agreement with WADA helping create early detection methods for performance-enhancing medicines in sport.
-
GlaxoSmithKline receives new approval for Rotarix and significant new indication for Lamictal® (lamotrigine) in Japan
GSK rotavirus vaccine approved for use in babies Lamotrigine becomes the first treatment to be approved in Japan for adult bipolar disorder
-
GSK welcomes external scientists to diseases of the developing world research campus
GSK will provide support, expertise and facilities as part of our open innovation strategy to spur global collaboration in research
-
GSK statement on University of East Anglia study examining health impacts of anticholinergic medicines for over 65s
University of East Anglia published in JAGS, long term health impacts of anticholinergic medicines, group of drugs taken by older people.
-
GSK statement on agreements with State Attorneys General on former Cidra manufacturing facility
GSK agreed to pay $40.75 million as part of an agreement related to events during early 2000s at former manufacturing facility in Cidra
-
GSK to purchase Shenzhen Neptunus stake in previously formed joint venture for influenza vaccines in China
GSK entered into agreement to acquire the remaining 51% equity interest of Neptunus in JV company for a total cash consideration of $39m
-
GlaxoSmithKline and Valeant announce US FDA approval of Potiga™ (ezogabine)
GSK & VRX announced that the FDA has approved Potiga Tablets, a potassium channel opener, as treatment of partial-onset seizures in 18yo+.
-
Millions of children in the world’s poorest countries could receive vaccination against rotavirus diarrhoeal disease under new offer made by GSK to the GAVI Alliance
GSK announced it's made a new offer to supply Rotarix, to the GAVI Alliance at $2.50 per dose, a small fraction of developed world prices.
-
GlaxoSmithKline’s pazopanib improved progression free survival in adults with certain soft tissue sarcomas
PALETTE study presented at ASCO demonstrated improvement in the time to occurrence of tumour progression in patients on pazopanib vs placebo